International multicenter investigation of LB20304, a new fluoronaphthyridone

Clinical Microbiology and Infection

Volumn 4, Issue 5, 1998, Pages 280-284

  Hohl, Annik F ^a   Frei, Reno ^a   Pünter, Verena ^b   Von Graevenitz, Alexander ^b   Knapp, Cynthia ^c   Washington, John ^c   Johnson, David ^d   Jones, Ronald N ^d  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c LERNER RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CIPROFLOXACIN; CLINAFLOXACIN; FLEROXACIN; GEMIFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; TROVAFLOXACIN; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; MULTICENTER STUDY; NONHUMAN; PRIORITY JOURNAL;

EID: 0031804178     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1469-0691.1998.tb00057.x     Document Type: Article

References (8)

1. Kim Y-K, Choi H, Kim S-H, et al. Synthesis and antibacterial activities of LB20304: a new fluoronaphthyridone antibiotic containing novel oxime functionalized pyrrolidine. In: Proceedings of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC. American Society for Microbiology, 1995: 148.
2. Oh J-I, Ahn M-H, Pack K-S, et al. In vitro and in vivo evaluations of LB20304, a new fluoronaphthyridone. Antimicrob Agents Chemother 1996; 40: 1564-8.
3. Cormican MG, Jones RN. Antimicrobial activity and spectrum of LB20304, a novel fluoronaphthyridone. Antimicrob Agents Chemother 1997; 41: 204-11.
4. American Society for Microbiology. Manual of clinical microbiology, 6th edn. Washington, DC: American Society for Microbiology, 1996.
5. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A4. Villanova, PA: NCCLS, 1997.
6. Domagala JM Structure-activity and structure-side-effect relationship for the quinolone antibacterials. J Antimicrob Chemother 1994; 33: 685-706.
7. Ritz M. Lode L, Fassbender M, Borner K, Koeppe P, Nord CE. Multiple-dose pharmacokinetics of sparfloxacin and its influence on fecal flora. Antimicrob Agents Chemother 1994; 38: 455-9.
8. Teng R, Liston TE, Harris SC. Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers. J Antimicrob Chemother 1996; 37: 955-63.